|
Tuesday,
March 9, 2010
“Laminin332 in Triple Negative
Breast Carcinoma”
Philip M. Carpenter, MD
Professor of Clinical Pathology
University of California Irvine
To preview the topic of
this academic program, you may wish to access Dr. Carpenter’s recent
publications in this field, cited below:
Motility induction in breast carcinoma by mammary epithelial laminin
332 (laminin 5).
Carpenter PM, Dao AV, Arain ZS, Chang MK, Nguyen HP, Arain S,
Wang-Rodriguez J, Kwon SY, Wilczynski SP.
Mol Cancer Res. 2009 Apr;7(4):462-75.
Laminin 5 expression in metaplastic breast carcinomas.
Carpenter PM, Wang-Rodriguez J, Chan OT, Wilczynski SP.
Am J Surg Pathol. 2008 Mar;32(3):345-53.
|
|
Objectives of Program:
- Understand the biological effects of laminin 332 on breast
cancer cells.
- Understand the staining characteristics of laminin 332 in breast
cancer.
- Understand the basal phenotype and triple negative phenotypes of
breast cancer and their potential role in diagnosis and treatment.
- Provide program participants with challenging and interesting
cases of use in everyday pathology practice.
IDENTIFIED NEED:
Identified by membership as valuable for its
provision of information in the field of Pathology.
The Los Angeles Society of Pathologists, Inc. is accredited by the
Institute for Medical Quality and the California Medical Association to
provide continuing medical education for physicians. The Los Angeles
Society of Pathologists, Inc. takes responsibility for the content,
quality and scientific integrity of this CME activity.
The Los Angeles Society of Pathologists, Inc. designates this
educational activity for a maximum of 1.5 AMA PRA Credit(s)TM.
Physicians should only claim credit commensurate with the extent of
their participation in the activity. This credit may also be applied to
the CMA Certification in Continuing Medical Education.
|